Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P. Di Paolo D, et al. Among authors: emionite l. Mol Ther. 2011 Dec;19(12):2201-12. doi: 10.1038/mt.2011.142. Epub 2011 Aug 9. Mol Ther. 2011. PMID: 21829174 Free PMC article.
New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destafanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P. Di Paolo D, et al. Among authors: emionite l. Oncotarget. 2015 Oct 6;6(30):28774-89. doi: 10.18632/oncotarget.4342. Oncotarget. 2015. PMID: 26299615 Free PMC article.
A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity in vivo.
Amaro A, Angelini G, Mirisola V, Esposito AI, Reverberi D, Matis S, Maffei M, Giaretti W, Viale M, Gangemi R, Emionite L, Astigiano S, Cilli M, Bachmeier BE, Killian PH, Albini A, Pfeffer U. Amaro A, et al. Among authors: emionite l. Oncotarget. 2016 Oct 18;7(42):68803-68820. doi: 10.18632/oncotarget.11931. Oncotarget. 2016. PMID: 27626697 Free PMC article.
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, Quintarelli C, Pezzolo A, Raffaghello L, Morandi F, Locatelli F, Pistoia V, Prigione I. Bocca P, et al. Among authors: emionite l. Oncoimmunology. 2017 Oct 4;7(1):e1378843. doi: 10.1080/2162402X.2017.1378843. eCollection 2017. Oncoimmunology. 2017. PMID: 29296542 Free PMC article.
A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L. Sidarovich V, et al. Among authors: emionite l. Mol Cancer Ther. 2018 Jul;17(7):1405-1415. doi: 10.1158/1535-7163.MCT-17-0841. Epub 2018 Apr 25. Mol Cancer Ther. 2018. PMID: 29695637
Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models.
Di Paolo D, Pastorino F, Brignole C, Corrias MV, Emionite L, Cilli M, Tamma R, Priddy L, Amaro A, Ferrari D, Marotta R, Ferretti E, Pfeffer U, Ribatti D, Sementa AR, Brown D, Ikegaki N, Shimada H, Ponzoni M, Perri P. Di Paolo D, et al. Among authors: emionite l. Small. 2020 May;16(20):e1906426. doi: 10.1002/smll.201906426. Epub 2020 Apr 22. Small. 2020. PMID: 32323486
86 results